

Nirav N Shah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4471862/publications.pdf>

Version: 2024-02-01

132
papers

3,239
citations

186209

28
h-index

189801

50
g-index

133
all docs

133
docs citations

133
times ranked

4425
citing authors

#	ARTICLE	IF	CITATIONS
1	Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. <i>Nature Medicine</i> , 2020, 26, 1569-1575.	15.2	266
2	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet</i> , The, 2021, 397, 892-901.	6.3	260
3	Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. <i>Blood</i> , 2020, 135, 1739-1749.	0.6	176
4	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 415-422.	0.8	162
5	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517.	1.7	135
6	Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 146.	1.3	123
7	National Marrow Donor Programâ€“Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2021, 39, 1971-1982.	0.8	90
8	Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. <i>Cytotherapy</i> , 2018, 20, 394-406.	0.3	89
9	Râ€“ <i>sc</i> p>CHOP </i><i> versus </i> doseâ€“adjusted Râ€“ <i>sc</i> p>EPOCH</i> in frontline management of primary mediastinal Bâ€“cell lymphoma: a multiâ€“centre analysis. <i>British Journal of Haematology</i> , 2018, 180, 534-544.	1.2	70
10	Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1689-1694.	2.0	70
11	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	2.0	61
12	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019, 25, 4264-4270.	3.2	61
13	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	2.5	55
14	Outcomes of frontâ€“line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , 2018, 93, 1394-1401.	2.0	52
15	Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?. <i>Blood</i> , 2021, 137, 1416-1423.	0.6	49
16	Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 720-727.	2.0	47
17	Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor â€“T-cell therapy in B-cell non-Hodgkin lymphomas. <i>Cytotherapy</i> , 2018, 20, 1415-1418.	0.3	45
18	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021, 7, 993.	3.4	44

#	ARTICLE	IF	CITATIONS
19	CAR T-cell therapy for secondary CNS DLBCL. <i>Blood Advances</i> , 2021, 5, 5626-5630.	2.5	41
20	Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients. <i>Transplant International</i> , 2013, 26, 616-622.	0.8	40
21	Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 909-913.	2.0	39
22	Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. <i>Blood Advances</i> , 2020, 4, 467-476.	2.5	39
23	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. <i>Haematologica</i> , 2018, 103, 717-727.	1.7	38
24	Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. <i>Blood Advances</i> , 2019, 3, 2836-2844.	2.5	38
25	Peripheral Blood Grafts for T Cell-replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1664-1670.	2.0	36
26	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.	2.5	35
27	Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. <i>Cancer Cell</i> , 2022, 40, 340-342.	7.7	35
28	Daratumumab in Primary Effusion Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 689-690.	13.9	33
29	Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. <i>Blood Advances</i> , 2020, 4, 2119-2122.	2.5	32
30	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. <i>Journal of Hematology and Oncology</i> , 2019, 12, 6.	6.9	29
31	Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. <i>BMC Cancer</i> , 2018, 18, 593.	1.1	28
32	Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. <i>Oncologist</i> , 2019, 24, 955-962.	1.9	28
33	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	2.5	27
34	Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2523.	1.7	27
35	Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?. <i>Journal of Clinical Oncology</i> , 2021, 39, 487-498.	0.8	27
36	A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 4193-4193.	0.6	27

#	ARTICLE	IF	CITATIONS
37	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	2.5	26
38	Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2019, 3, 4136-4146.	2.5	26
39	Improving the Safety of Oral Chemotherapy at an Academic Medical Center. <i>Journal of Oncology Practice</i> , 2016, 12, e71-e76.	2.5	25
40	Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1955-1960.	2.0	24
41	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1492-1497.	2.0	23
42	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 827-833.	2.0	23
43	Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. <i>Blood Advances</i> , 2019, 3, 1661-1669.	2.5	21
44	A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2021, 138, 740-740.	0.6	21
45	Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 335-342.	2.0	20
46	Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. <i>Blood Advances</i> , 2020, 4, 47-54.	2.5	20
47	Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas. <i>American Journal of Hematology</i> , 2019, 94, S18-S23.	2.0	19
48	Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. <i>Current Treatment Options in Oncology</i> , 2020, 21, 16.	1.3	19
49	The role of ¹⁸ F-FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma. <i>Cancer Medicine</i> , 2015, 4, 7-15.	1.3	18
50	Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1456-1464.	2.0	18
51	Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease: Results from the Phase 2 REACH1 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S52.	2.0	18
52	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	2.5	18
53	Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1670-1678.	2.0	17
54	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2020, 136, 35-37.	0.6	16

#	ARTICLE	IF	CITATIONS
55	Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 113-121.	0.7	15
56	Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 56.	2.8	15
57	Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. <i>Leukemia and Lymphoma</i> , 2020, 61, 869-874.	0.6	14
58	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
59	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 893-901.	2.0	13
60	Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease. <i>Blood</i> , 2018, 132, 601-601.	0.6	13
61	Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. <i>JAMA Network Open</i> , 2019, 2, e196476.	2.8	12
62	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	1.3	12
63	Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?. <i>Cytotherapy</i> , 2021, 23, 985-990.	0.3	12
64	Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies. <i>Blood</i> , 2019, 134, 5329-5329.	0.6	12
65	CAR-T Cell Production Using the Clinimacs® Prodigy System. <i>Blood</i> , 2016, 128, 5724-5724.	0.6	12
66	A Phase II Single Arm Study of Nivolumab As Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma at Risk of Relapse or Progression. <i>Blood</i> , 2021, 138, 2455-2455.	0.6	12
67	Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. <i>Blood Cancer Journal</i> , 2019, 9, 97.	2.8	11
68	Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. <i>JAMA Oncology</i> , 2022, 8, 773.	3.4	11
69	Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e33-e38.	2.0	10
70	Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. <i>Cytotherapy</i> , 2022, 24, 767-773.	0.3	10
71	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 78-85.	2.0	9
72	Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 834-841.	2.0	9

#	ARTICLE	IF	CITATIONS
73	Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. <i>Oncologist</i> , 2019, 24, 1488-1495.	1.9	9
74	Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 95-102.	0.2	9
75	Extracavitary Primary Effusion Lymphoma Initially Presenting With Hemophagocytic Lymphohistocytosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e157-e160.	0.2	8
76	Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1610-1614.	2.0	8
77	Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study. <i>Blood</i> , 2021, 138, 567-567.	0.6	8
78	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021, 138, 381-381.	0.6	8
79	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021, 138, 391-391.	0.6	8
80	Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistocytosis. <i>American Journal of Hematology</i> , 2016, 91, 1161-1164.	2.0	7
81	Alpha-1 antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. <i>American Journal of Hematology</i> , 2017, 92, E610-E611.	2.0	7
82	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. <i>Bone Marrow Transplantation</i> , 2018, 53, 1210-1213.	1.3	7
83	Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 884-884.	0.6	7
84	Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 305-311.e2.	0.2	6
85	Leukemic phase and CSF involvement of diffuse large B-cell lymphoma with a complex karyotype including a TP53 deletion. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 235-237.	0.2	6
86	Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 4465-4465.	0.6	6
87	Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 29-30.	0.6	6
88	Acute promyelocytic leukemia presenting as a paraspinal mass. <i>Journal of Community and Supportive Oncology</i> , 2016, 14, 126-129.	0.1	6
89	Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL. <i>Blood</i> , 2018, 132, 4553-4553.	0.6	5
90	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2020, 136, 8-10.	0.6	5

#	ARTICLE	IF	CITATIONS
91	Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative. <i>Blood</i> , 2020, 136, 48-49.	0.6	5
92	Single-Cell RNA Sequencing Identifies Expression Patterns Associated with Clinical Responses to Dual-Targeted CAR-T Cell Therapy. <i>Blood</i> , 2020, 136, 33-34.	0.6	5
93	Mimicking Myelodysplastic Syndrome: Importance of Differential Diagnosis. <i>Case Reports in Hematology</i> , 2021, 2021, 1-3.	0.3	5
94	Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy. <i>Communications Medicine</i> , 2022, 2, .	1.9	5
95	Bispecific CAR T-cells for B-cell Malignancies. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1005-1015.	1.4	5
96	Implementation of an Advanced Practice Provider Service on an Allogeneic Stem Cell Transplant Unit: Impact on Patient Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1692-1698.	2.0	4
97	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1876-1885.	2.0	4
98	PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response. <i>Haematologica</i> , 2021, 106, 2788-2790.	1.7	4
99	Quality of Life, Tryptophan Metabolites, and Neurotoxicity Assessments of Patients with Relapsed or Refractory B Cell Malignancies Undergoing CAR 20/19 - T Cell Therapy. <i>Blood</i> , 2020, 136, 42-43.	0.6	3
100	Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 863-868.	0.2	3
101	Graft-versus-host disease-associated hepatic portal venous gas. <i>British Journal of Haematology</i> , 2018, 181, 9-9.	1.2	2
102	Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 210-215.	1.4	2
103	Transplantation Using Bone Marrow from a (very) HLA Mismatched Unrelated Donor in the Setting of Post-Transplant Cyclophosphamide Is Feasible and Expands Access to Underserved Minorities. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S283-S284.	2.0	2
104	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. <i>Blood</i> , 2018, 132, 1015-1015.	0.6	2
105	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. <i>Blood</i> , 2018, 132, 3142-3142.	0.6	2
106	A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen. <i>Blood</i> , 2020, 136, 44-45.	0.6	2
107	Brentuximab Vedotin in Combination with Multi-Agent Chemotherapy Is Well Tolerated and Shows Promising Activity As Frontline Treatment for Primary Mediastinal B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 2694-2694.	0.6	2
108	Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 & IL-15 for a Shorter Duration Improves CAR T-Cell Immunophenotype While Maintaining Target Cell Dose. <i>Blood</i> , 2021, 138, 3883-3883.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 95-95.	0.6	2
110	Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial. <i>Blood</i> , 2020, 136, 22-22.	0.6	2
111	<p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2020, Volume 10, 1-5.	1.2	1
112	Treatment-Emergent Tumor Lysis Syndrome With PI3KÎ³ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia. <i>JCO Oncology Practice</i> , 2020, 16, 613-614.	1.4	1
113	A Phase 1b Study of Intravenous Vedolizumab Plus Standard of Care for Graft-Versus-Host Disease Prophylaxis in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: 6-Month Results. <i>Blood</i> , 2018, 132, 605-605.	0.6	1
114	Outcomes of Grade 3A Follicular Lymphoma: Best Treated As Aggressive or Indolent Lymphoma?. <i>Blood</i> , 2016, 128, 5328-5328.	0.6	1
115	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. <i>Blood</i> , 2021, 138, 532-532.	0.6	1
116	Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy. <i>Blood</i> , 2021, 138, 3043-3043.	0.6	1
117	Associations between Socioeconomic Status and Bispecific LV20.19 CAR T-Cell Therapy Outcomes. <i>Blood</i> , 2021, 138, 4084-4084.	0.6	1
118	Successful Manufacturing of CAR T-Cells with Small Volume Peripheral Blood from Healthy Donors Using the Clinimacs Prodigy Device. <i>Blood</i> , 2020, 136, 27-28.	0.6	1
119	What is the standard of care for primary mediastinal B cell lymphoma; Râ€<sc>CHOP</sc> or <sc>DA</sc>â€<sc>EPOCH</sc>â€? â€“ Response to Melani <i>etÂal</i>. <i>British Journal of Haematology</i> , 2019, 184, 838-840.	1.2	0
120	Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e775-e781.	0.2	0
121	The Impact of Autoimmune Disease on Clinical Outcomes of Patients with DLBCL and FL. <i>Blood</i> , 2014, 124, 2974-2974.	0.6	0
122	Impact of Obesity on Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies. <i>Blood</i> , 2016, 128, 4667-4667.	0.6	0
123	Improvements in Clinical Outcomes of Advanced Stage Classical Hodgkin Lymphoma in the United States from 2000-2014: Analysis of Surveillance Epidemiology and End Results Database. <i>Blood</i> , 2018, 132, 2939-2939.	0.6	0
124	Incidence and Predictors of 30-Day Readmissions Following Autologous Hematopoietic Cell Transplantation (auto-HCT) in the US. <i>Blood</i> , 2018, 132, 3544-3544.	0.6	0
125	Trends in Post-Relapse Survival in Classical Hodgkin Lymphoma Patients after Experiencing Therapy Failure Following Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 2918-2918.	0.6	0
126	Association between Transplant Volumes and 30-Day Readmissions Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in the US. <i>Blood</i> , 2018, 132, 617-617.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings. <i>Blood</i> , 2018, 132, 4410-4410.	0.6	0
128	Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2018, 132, 1998-1998.	0.6	0
129	Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2. <i>Blood</i> , 2021, 138, 1728-1728.	0.6	0
130	Allogeneic Transplant Outcomes for T-Cell Lymphomas: A Single Center Analysis. <i>Blood</i> , 2020, 136, 20-21.	0.6	0
131	Hemophagocytosis in cerebrospinal fluid after CAR T-cell therapy. <i>Blood</i> , 2022, 139, 1116-1116.	0.6	0
132	Rap1A, Rap1B, and β -Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol. <i>Yale Journal of Biology and Medicine</i> , 2022, 95, 45-56.	0.2	0